StephenBarriHeitnerMDFACC, FASE
Cardiology • Portland, ORAdult Congenital Heart Disease, Echocardiography, Heart Failure & Transplantation
Senior Medical Director, cardiovascular Cytokinetics inc.
Dr. Heitner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 Sw Sam Jackson Park Road
Division Of Cardiology Ohsu
Portland, OR 97239Phone+1 503-494-7400Fax+1 503-418-9195- Is this information wrong?
Summary
- Dr. Stephen Heitner is a cardiologist in Portland, OR and is affiliated with OHSU Hospital. He received his medical degree from University of the Witwatersrand and has been in practice 18 years. He specializes in adult congenital heart disease, echocardiography, and heart failure & transplantation and is experienced in general cardiology, echocardiography, nuclear cardiology, and advanced cardiac imaging.
Education & Training
Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Cardiovascular Disease, 2008 - 2011
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2004 - 2008
University of the WitwatersrandClass of 1999
Certifications & Licensure
OR State Medical License 2011 - 2025
CA State Medical License 2019 - 2025
PA State Medical License 2004 - 2012
NJ State Medical License 2009 - 2011
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Fellow (FACC) American College of Cardiology
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
- Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) Start of enrollment: 2020 Sep 21
Publications & Presentations
PubMed
- EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.Castaño, A., Huda, A., Calambur, V., Bruno, M., Schumacher, J., Emir, B., Isherwood, C., Heitner, S., Masri, A., Shah, S.> ;Journal of Cardiac Failure. 2023 Dec 7
- 6 citationsAficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, John D Symanski, Aslan T Turer, Timothy C Wong, Albree Tower-Rader, Caroline J Coats, ...> ;Journal of Cardiac Failure. 2023 Nov 1
- 4 citationsLimitations of gene editing assessments in human preimplantation embryos.Dan Liang, Aleksei Mikhalchenko, Hong Ma, Nuria Marti Gutierrez, Tailai Chen, Yeonmi Lee, Sang-Wook Park, Rebecca Tippner-Hedges, Amy Koski, Hayley Darby, Ying Li, Cry...> ;Nature Communications. 2023 Mar 7
- Join now to see all
Journal Articles
- Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryStephen Heitner, MD, JAMA Cardiology
Abstracts/Posters
- [Board 518] Long-Term Safety and Effectiveness of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients PIONEER-Open Label Extension Study (PIONE...Stephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/17/2019
- [Board 279] Implantable Cardioverter-Defibrillators For Children With Cardiac Conditions Associated With High Risk For Sudden Cardiac Death: A Cost-Effectiveness Analy...Stephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/16/2019
- [Board 561] Home AEDs For Children With Cardiac Conditions Associated With Intermediate Risk For Sudden Cardiac Death: A Cost-Effectiveness AnalysisStephen Heitner, 2019 ACC Scientific Session & Expo, New Orleans, New Orleans, 3/16/2019
Authored Content
- Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in HistoryJune 2020
Press Mentions
48-Week Results for Mavacamten Draw Crowd at AHA SessionNovember 18th, 2019
MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019Company to Host Conference Call and Webcast on November 11, 2019 at 8:30 a.m. ET (5:30 a.m. PT)November 4th, 2019
New Study of Ultrasound Enhancing Agents in Echocardiography Reaffirms Safety Profile of LUMASON® (Sulfur Hexafluoride Lipid-Type A Microspheres) for Injectable Suspension, for Intravenous Use or Intravesical UseJuly 15th, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
